Results 171 to 180 of about 7,028 (198)

Necrotizing scleritis resistant to biologics successfully managed with the JAK inhibitor upadacitinib: a case report. [PDF]

J Ophthalmic Inflamm Infect
Oyama T, Nakai S, Miyao K, Imazeki M, Takeuchi M.   +4 more
europepmc   +1 more source

Upadacitinib for atopic dermatitis induced by secukinumab in patients with refractory ankylosing spondylitis:a case report. [PDF]

Front Immunol
Fang J, Pan S.
europepmc   +1 more source

Successful treatment of cutaneous small-vessel vasculitis with upadacitinib: a Case Report. [PDF]

Front Med (Lausanne)
Li X, Wu Z, Zhao X, Liu L, Li H, Zhang G, Zhu Q.   +6 more
europepmc   +1 more source

Atopic Dermatitis During Ustekinumab Therapy in a Patient With Ulcerative Colitis: A Case Report and Review of Targeted Therapies in Coexisting Diseases. [PDF]

Cureus
Maeyama A, Inoue T, Sugita K.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Upadacitinib

Reactions Weekly
  +39 more sources

Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review [PDF]

Journal of Clinical Medicine, 2023
Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA) at a dose of 15 mg/day.
Raimon Sanmartí, Hector Corominas, Sanmartí Raimon   +2 more
exaly   +5 more sources

Upadacitinib

Reactions Weekly, 2023
  +10 more sources

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials [PDF]

Lancet, The, 2022
BACKGROUND There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative colitis.
Aileen L Pangan, Jesse Siffledeen, Julian Panes   +2 more
exaly   +2 more sources

Upadacitinib

Reactions Weekly, 2022
openaire   +1 more source